



10-16.00



EK695077953US

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" mailing label number:

Date of Mailing: October 13, 2000

UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service, utilizing the "Express Mail Post Office to Addressee" service addressed to Assistant Commissioner for Patents, Washington, DC 20231 and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.

Tracy L. Morton
Signature Date: October 13, 2000

1c922 U.S. PTO 09/687230 10/13/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION	
Inventor(s):	Sylvia Braselmann))	Group:	1652
SC/Serial No.:	Unknown))	Examiner:	Tung, P.
Filed:	Herewith))		
Title: Nucleotide Sequences that Encode Phosphatidylinositol-3' Kinase Associated Proteins and Uses Thereof))))	•	

APPLICATION TRANSMITTAL LETTER FOR A DIVISIONAL PATENT APPLICATION UNDER 37 C.F.R. §1.53(b)

Box Patent Application Assistant Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith for filing is a Divisional Patent Application, of U.S. Application Serial No. 08/942,008, filed October 1, 1997, now U.S. Patent No. 6,133,419, issuing on October 17, 2000, which claims priority from U.S. Application Serial No. 60/030,103, filed November 1, 1996, identified as follows:

Inventor(s): Sylvia Braselmann

Resident of: 4828 19th Street, San Francisco, CA 94114

Title: Nucleotide Sequences that Encode Phosphatidylinositol-3' Kinase

Associated Proteins and Uses Thereof

No. of pages in Specification: 48; No. of Claims: 22

-1-

Attorney Docket No.: ONYX1027-DIV1 Onyx1027-DIV/Formal Papers/DIV-TM 200.004 10/13/2000-10:00 AM





Also enclosed are:

- [X] A Declaration.
- [X] An Assignment and Recordation Form Cover Sheet.
- [X] A certified copy of a priority application.
- [X] A Sequence Listing (Paper and CRF copies).
- [X] A Preliminary Amendment.

The filing fee pursuant to 37 C.F.R. § 1.16 is determined as follows:

No. Filed	No. Extra		Rate Small Entity Large Entity	<i>'</i>	
Basic					
Fee			\$355.00		
			710.00	=	\$ <u>710.00</u>
Total					
Claims 22 - 20 =	2	* 7	\$ 9.00		
			18.00	=	\$36.00
Independent			-	· · · ·	
Claims 6 - 3 =	3	* 7	\$ 40.00		
			80.00	=	\$ <u>120.00</u>
First Presentation of					
Multiple Dependent Claim(s) 0		9	\$135.00		
			270.00	=	\$0
			Total:	=	\$866.00

^{*}If the difference is less than zero, enter "0".

- [X] Please charge Deposit Account No. 15-0615 in the amount of \$906.00 (\$866.00 Filing Fee; and \$40.00 Assignment Recording Fee). A duplicate copy of this authorization is enclosed.
- [X] The Commissioner is hereby authorized to charge any fees associated with this communication (including those listed below) to Deposit Account No. 15-0615. A duplicate copy of this authorization is enclosed.
 - [X] Any additional filing fees under 37 C.F.R. § 1.16.
 - [X] Any patent application processing fees under 37 C.F.R. § 1.17.

This application is filed pursuant to 37 C.F.R. § 1.53 in the name of the aboveidentified Inventor(s).

Please direct all correspondence concerning the above-identified application to the following address:

> Gregory Giotta, Ph.D. Vice President and Chief Legal Counsel ONYX Pharmaceuticals, Inc. 3031 Research Drive Richmond, California 94806 Telephone: (510) 262-8710

> > Respectfully submitted,

Date: October 13, 2000

Reg. No. 32,028

ONYX Pharmaceuticals, Inc. 3031 Research Drive Richmond, California 94806

Telephone:

(510) 222-9700

Facsimile:

(510) 222-9700